PLAUR and colorectal cancer: compared the application of a highly specific high‐affinity anti‐uPAR antibody (MNPR‐101) and its Fab and F(ab’)2 fragments, respectively at 96, 48, and 36 h in head and neck, pancreatic and colorectal cancers.